Immunome, Inc.
Price Action
Technical Summary
EMERGING TRENDImmunome, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 85), indicating clear outperformance against the broad market. Earnings growth of 41% provides fundamental context to the price action. Investors should exercise caution due to high volatility (72% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $23.25 | +0.10% | ABOVE |
| 50 SMA | $21.98 | +5.87% | ABOVE |
| 100 SMA | $22.30 | +4.35% | ABOVE |
| 150 SMA | $20.37 | +14.26% | ABOVE |
| 200 SMA | $17.82 | +30.60% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is IMNM in an uptrend right now?
IMNM has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is IMNM overbought or oversold?
IMNM's RSI (14) is 53. The stock is in neutral territory, neither overbought nor oversold.
Is IMNM outperforming the market?
IMNM has a Relative Strength (RS) Rating of 85 out of 99. Yes, IMNM is a market leader, outperforming 85% of all stocks over the past 12 months.
Where is IMNM in its 52-week range?
IMNM is trading at $23.27, which is 84% of its 52-week high ($27.65) and 79% above its 52-week low ($7.15).
How volatile is IMNM?
IMNM has a Beta of 2.08 and 52-week volatility of 72%. It's more volatile than the S&P 500 - expect bigger swings.